NCT04865419 2025-06-15
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
AstraZeneca
Phase 1 Terminated
Clinical Trials
21 trialsNCT02014558 2024-12-03
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Astellas Pharma Inc
Phase 1/2 Completed
NCT04551963 2024-10-26
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
BeiGene
Phase 1 Completed
NCT01686607 2024-10-21
MYCOS
Astellas Pharma Inc
Completed
NCT01503515 2024-10-16
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Children's Oncology Group
Phase 3 Completed
NCT00075803 2023-01-04
BMT CTN 0101
Medical College of Wisconsin
Phase 3 Completed
NCT04547335 2020-09-16
The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole
Dokuz Eylul University
Unknown
NCT02381080 2017-06-26
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Janssen Research & Development, LLC
Phase 1 Completed
NCT00893555 2017-01-12
VORI911
University Medical Center Groningen
Phase 3 Completed
NCT01416025 2016-08-18
VoriTDM
Johns Hopkins University
Phase 4 Completed
NCT01501708 2016-05-10
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT00023530 2016-02-18
Blood and Marrow Transplant Clinical Research Network
National Heart, Lung, and Blood Institute (NHLBI)
Phase NA Completed
NCT01148160 2014-04-10
Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
Asan Medical Center
Terminated
NCT00059878 2013-06-19
Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections
National Cancer Institute (NCI)
Phase 2 Completed
NCT01480219 2013-03-11
Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g
Pfizer
Completed
NCT00418951 2012-08-07
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00904995 2012-08-07
Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01207128 2012-04-20
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
University of Arkansas
Phase 2 Withdrawn
NCT00143312 2009-10-06
VOSIFI
Pfizer
Phase 4 Completed
NCT00015665 2008-03-04
Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00152594 2006-11-14
Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
University of Cologne
Phase 3 Terminated